Impact of Thrombopoietin Receptor Agonists on Pathophysiology of Pediatric Immune Thrombocytopenia

Impact of Thrombopoietin Receptor Agonists on Pathophysiology of Pediatric Immune Thrombocytopenia

Immune thrombocytopenia (ITP) in pediatric patients is a common cause of isolated thrombocytopenia. Various pathophysiological mechanisms are implicated in ITP pathogenesis, including the production of autoantibodies against components of platelets (PLTs) by B-cells, the activation of the complement...

Full description

Saved in:

Bibliographic Details
Main Authors:	Paschalis Evangelidis, Konstantinos Tragiannidis, Eleni Gavriilaki, Athanasios Tragiannidis
Format:	Article
Language:	English
Published:	MDPI AG 2025-01-01
Series:	Current Issues in Molecular Biology
Subjects:	eltrombopag immune thrombocytopenia pediatrics romiplostim thrombopoietin receptor agonists
Online Access:	https://www.mdpi.com/1467-3045/47/1/65
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Results of long-term treatment with thrombopoietin receptor agonists of resistant primary immune thrombocytopenia
by: O. Yu. Vinogradova, et al.
Published: (2024-12-01)

Complications of thrombopoietin receptor agonists therapy in patients with immune thrombocytopenia
by: S. G. Zakharov, et al.
Published: (2024-04-01)

A multicenter mixed-methods study on the effects of intermittent fasting in patients with immune thrombocytopenia receiving thrombopoietin receptor agonists
by: Mohamed A. Yassin, et al.
Published: (2025-02-01)

Should thrombopoietin receptor agonists be used for chemotherapy-induced thrombocytopenia?
by: Hanny Al-Samkari
Published: (2025-07-01)

The role of thrombopoietin receptor agonists in the management of adult primary immune thrombocytopenia: A single centre experience
by: Virijević Marijana, et al.
Published: (2022-01-01)

Thrombopoietin Receptor Agonists: Clinical Use and Evaluation of Treatment Efficacy
by: A. G. Solodovnikov, et al.
Published: (2020-12-01)

Thrombopoietin Receptor Agonists in Treatment of Idiopathic Thrompocytopenic Purpura (Primary Immune Thrombocytopenia): Efficacy and Safety in Everyday Clinical Practice
by: II Zotova, et al.
Published: (2017-01-01)

Thrombopoietin mutation in congenital amegakaryocytic thrombocytopenia treatable with romiplostim
by: Alessandro Pecci, et al.
Published: (2017-11-01)

Comparative efficacy and safety of rhTPO, romiplostim, and eltrombopag in the treatment of pediatric primary immune thrombocytopenia: a systematic review and network meta-analysis
by: Xiaofang Zhang, et al.
Published: (2025-06-01)

CLINICAL AND ECONOMIC EVALUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN THE TREATMENT OF CHRONIC IDIOPATHIC THROMBOCYTOPENIC PURPURA IN ADULTS
by: E. A. Pyadushkina, et al.
Published: (2016-02-01)

Correction of Thrombocytopenia before Elective Surgery / Invasive Procedures in Patients with Liver Cirrhosis (Experts’ Agreement)
by: M. V. Maevskaya, et al.
Published: (2024-08-01)

Pharmacoeconomic Analysis of the Use of Thrombopoietin Receptors Agonists in Idiopathic Thrombocytopenic Purpura Therapy
by: VA Shuvaev, et al.
Published: (2017-10-01)

PATHOBIOLOGY AND TREATMENT OF HEPATITIS VIRUS-RELATED THROMBOCYTOPENIA
by: Roberto Stasi, et al.
Published: (2009-11-01)

Correction of Thrombocytopenia with Thrombopoietin Receptor Agonists in Patients with Liver Cirrhosis Before Elective Surgery or Invasive Procedures
by: T. A. Deeva, et al.
Published: (2025-02-01)

Management of patients with immune thrombocytopenia in the Moscow region
by: S. G. Zakharov, et al.
Published: (2022-11-01)

Dose-optimised recombinant human thrombopoietin versus eltrombopag in patients with immune thrombocytopenia: a multicenter, randomised controlled trial (The TE-ITP Study)Research in context
by: Yunfei Chen, et al.
Published: (2025-09-01)

Experience of 2<sup>nd</sup> line therapy with eltrombopag in patients with immune thrombocytopenia
by: S. G. Zakharov, et al.
Published: (2023-09-01)

Cost-per-responder analysis for eltrombopag and rituximab in the treatment of primary immune thrombocytopenia in Spain
by: Eduardo Anguita, et al.
Published: (2020-11-01)

Case Report: Dangerous liaisons between splenectomy and eltrombopag-induced chronic thromboembolic pulmonary hypertension in patients with immune thrombocytopenia: report of two cases and review of the literature
by: Roberto Castelli, et al.
Published: (2025-02-01)

The Cost-Effectiveness of Avatrombopag Versus Eltrombopag and Romiplostim in the Treatment of Patients with Immune Thrombocytopenia in the UK
by: Nichola Cooper, et al.
Published: (2025-03-01)

Stepwise response-guided treatment protocol superior to thrombopoietin receptor agonist-based second-line therapy for severe persistent/chronic immune thrombocytopenia: a multicenter prospective study from China
by: Lingling Fu, et al.
Published: (2025-02-01)

Single or multiple treatments with lusutrombopag in subjects with thrombocytopenia and chronic liver disease needing an invasive procedure
by: Davide Scalabrini, et al.
Published: (2023-08-01)

Literature Review and Experts’ Opinion for Managing Thrombocytopenia in Chronic Liver Disease
by: Faisal Alsayegh, et al.
Published: (2025-01-01)

A case with a novel GATA1 variant mimicking immune thrombocytopenia attacks
by: Elif Habibe Aktekin, et al.
Published: (2025-12-01)

Triple antiviral therapy in patient with liver cirrhosis: complications and options of pharmacological treatment
by: M. V. Mayevskaya, et al.
Published: (2014-08-01)

Successful resection of intrahepatic cholangiocarcinoma with idiopathic thrombocytopenic purpura using thrombopoietin receptor agonist: a case report
by: Kouki Hoshino, et al.
Published: (2019-04-01)

Experience of off-label use of Eltrombopag in the treatment of thrombocytopenia associated with solid tumors
by: María Henar García Lagunar, et al.
Published: (2015-02-01)

Romiplostim in thrombocytopenia treatment after allogeneic bone marrow transplantation
by: I. A. Lisukov, et al.
Published: (2014-07-01)

Research progress in the treatment of chronic primary immune thrombocytopenia
by: HUANG Zhouxuan, et al.
Published: (2025-04-01)

Invasive Fungal Disease After Chimeric Antigen Receptor-T Immunotherapy in Adult and Pediatric Patients
by: Paschalis Evangelidis, et al.
Published: (2025-02-01)

The establishment of an expected concentration reference range for eltrombopag in the individualized treatment of pediatric immune thrombocytopenia
by: Nan Wang, et al.
Published: (2025-08-01)

Evaluation of the Efficacy of Romiplostim in Management of Chemotherapy-Induced Thrombocytopenia in Indian Patients: A Retrospective Study
by: Vikas Talreja, et al.

Effective treatment of refractory aplastic anemia with romiplostim after failure of multiple thrombopoietin receptor agonists: a single-center retrospective study
by: Xijuan Lin, et al.
Published: (2025-12-01)

Sustained response off treatment after fostamatinib in refractory immune thrombocytopenia: A series of four case reports
by: Waleed Ghanima, et al.
Published: (2025-12-01)

Acute myocardial infarction induced by avatrombopag: a case report
by: Gou Junqi, et al.
Published: (2025-08-01)

Case Report: A case of pediatric persistent refractory ITP responsive to avatrombopag
by: Antonella Sau, et al.
Published: (2025-04-01)

Real-world experience of hetrombopag in immune thrombocytopenia treatment: a retrospective cohort study
by: Dan Wang, et al.
Published: (2025-07-01)

Sequential Use of Efgartigimod and Romiplostim Restored Platelet Response in Two Multirefractory Thrombocytopenic Patients, Previously Treated with Thrombopoietin Receptor Agonists
by: Monica Carpenedo, et al.
Published: (2023-02-01)

Pharmacist intervention through protocol-based pharmacotherapy management is effective to ensure safety in invasive procedures for chronic liver disease
by: Yuuka Shibata, et al.
Published: (2025-08-01)

Observation on the efficacy of TPO receptor agonists and platelet transfusion in chemotherapy-induced thrombocytopenia in malignant tumors
by: Huan Hu, et al.
Published: (2025-01-01)